Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Phase 1 Ascending Dose Study of DCC-2701 To Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Patients With Advanced Solid Tumors

NCT02228811 is registered in ClinicalTrials.gov with Deciphera Pharmaceuticals, LLC as lead sponsor.

NCT NCT02228811
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02228811 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Phase 1 Ascending Dose Study of DCC-2701 To Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Patients With Advanced Solid Tumors
Lead sponsor
Deciphera Pharmaceuticals, LLC
Phase
Phase 1
Overall status
Terminated
Start date
June 30, 2014
Completion date
January 31, 2018
Enrollment
44 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

cancers with met genomic alterations, cancers with trk genomic alterations, locally advanced tumors, metastatic solid tumors